Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Methods of Documentation II: POMR01:26

Methods of Documentation II: POMR

1.5K
The Problem-Oriented Medical Record (POMR) revolutionized medical record-keeping by introducing a systematic approach focusing on the patient's problems rather than merely listing symptoms. Dr. Lawrence Weed's introduction of this method in the 1960s marked a significant advancement in medical documentation. The POMR framework consists of four key components: the database, problem list, plan of care, and progress notes.
1.5K
COP Coated Vesicles00:59

COP Coated Vesicles

18.4K
Membrane-enclosed structures called vesicles transport proteins and lipids across the cell. The vesicles derive their cargo from the plasma membrane, Golgi, ER, or endosome. Coated vesicles are spherical, protein-coated carriers with a 50–100 nm diameter that mediate bidirectional transport between the ER and the Golgi. The distribution of proteins between the ER and Golgi complex is dynamic and is maintained by different coated vesicles. Their formation is driven by the assembly of...
18.4K
Bioequivalence: Overview01:16

Bioequivalence: Overview

2.1K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.1K
Biopharmaceutics and Pharmacokinetics: Overview01:28

Biopharmaceutics and Pharmacokinetics: Overview

4.5K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
4.5K
Bioavailability: Overview01:17

Bioavailability: Overview

583
Bioavailability refers to the proportion of an administered drug that reaches the systemic circulation in its active, unaltered form. It is a crucial pharmacokinetic parameter that determines the effectiveness of a drug in achieving its intended therapeutic outcomes. The route of administration significantly influences bioavailability, with intravenous administration achieving 100% bioavailability as the drug directly enters the bloodstream. In contrast, oral administration often results in...
583
Bioavailability: Overview01:13

Bioavailability: Overview

4.7K
Bioavailability refers to the proportion of an unaltered drug that, after administration, enters the systemic circulation and can be distributed to the desired action site. Factors such as gastrointestinal (GI) absorption and liver biotransformation influence the bioavailability of a drug when it is administered orally. When a drug is administered intravenously, it enters the systemic circulation directly; by definition, its bioavailability is assumed to be 100%. The bioavailability of an...
4.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Profiling the long-term risk of severe adverse events in a cohort of multiple sclerosis patients treated with different treatment sequences: Results from the Italian Multiple Sclerosis and Related Disorders Registry (I-MS&RD) (ProSA study).

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Predictive factors of response to anti-CGRP pathway drugs in people with multiple sclerosis.

The journal of headache and pain·2026
Same author

Long-term outcomes of autologous haematopoietic stem cell transplantation in multiple sclerosis: A retrospective single-centre experience.

Multiple sclerosis journal - experimental, translational and clinical·2026
Same author

From Marginal to Central: Marginal Zone-like B Cells as Critical Targets in Cladribine-Treated Multiple Sclerosis.

Annals of neurology·2026
Same author

Task-oriented virtual reality and brain functional plasticity in progressive multiple sclerosis: A randomized controlled trial on upper limb rehabilitation.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

ATM-kinase deficiency triggers early multi-compartment remodeling of the cerebellar microenvironment.

Acta neuropathologica communications·2026

Related Experiment Video

Updated: Feb 25, 2026

Development of Compendium for Esophageal Squamous Cell Carcinoma
03:36

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

874

A Comprehensive Review on Copemyl®.

Pietro Annovazzi1, Antonio Bertolotto2, Vincenzo Brescia Morra3

  • 1Multiple Sclerosis Study Center, ASST Valle Olona, Gallarate, VA, Italy. pietro.annovazzi@asst-valleolona.it.

Neurology and Therapy
|August 2, 2017
PubMed
Summary
This summary is machine-generated.

New glatiramide acetate versions offer economic sustainability for multiple sclerosis (MS) treatment. This review examines regulatory approvals and clinical data for Copemyl®, a new glatiramide drug.

Keywords:
BioequivalenceCopemyl®Glatiramer acetateGlatiramoidMultiple sclerosisNon-biological complex drugs

More Related Videos

Controlled Odor Mimic Permeation Systems for Olfactory Training and Field Testing
05:54

Controlled Odor Mimic Permeation Systems for Olfactory Training and Field Testing

Published on: January 28, 2021

5.1K
Glycan Profiling of Plant Cell Wall Polymers using Microarrays
12:30

Glycan Profiling of Plant Cell Wall Polymers using Microarrays

Published on: December 17, 2012

15.2K

Related Experiment Videos

Last Updated: Feb 25, 2026

Development of Compendium for Esophageal Squamous Cell Carcinoma
03:36

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

874
Controlled Odor Mimic Permeation Systems for Olfactory Training and Field Testing
05:54

Controlled Odor Mimic Permeation Systems for Olfactory Training and Field Testing

Published on: January 28, 2021

5.1K
Glycan Profiling of Plant Cell Wall Polymers using Microarrays
12:30

Glycan Profiling of Plant Cell Wall Polymers using Microarrays

Published on: December 17, 2012

15.2K

Area of Science:

  • Pharmacoeconomics
  • Neurology
  • Drug Development

Background:

  • Economic sustainability is crucial in multiple sclerosis (MS) therapeutics.
  • Glatiramer acetate, a disease-modifying drug (DMD) for MS, has been available for over 20 years.
  • Patent expiration in 2015 has led to new glatiramide versions, potentially reducing costs.

Purpose of the Study:

  • To review regulatory approval recommendations for generic and biosimilar drugs.
  • To provide methodological tools for designing studies on new drug classes.
  • To analyze preclinical and clinical data for Copemyl®, a new glatiramide.

Main Methods:

  • Review of regulatory authority recommendations for generic and biosimilar drug approvals.
  • Methodological analysis for study design in new drug classes.
  • Examination of preclinical and clinical data for Copemyl®.

Main Results:

  • Analysis of regulatory pathways for generic and biosimilar glatiramide drugs.
  • Evaluation of Copemyl®'s biological and immunological profile.
  • Summary of randomized controlled trials supporting Copemyl® authorization.

Conclusions:

  • New glatiramide versions like Copemyl® can enhance economic sustainability in MS treatment.
  • Regulatory frameworks support the approval of these new therapeutic options.
  • Copemyl® demonstrates favorable properties and efficacy, contributing to resource allocation.